Lifesaving liver disease medicines

Our mission

Versantis develops a new generation of liver disease therapeutics and diagnostics.

We are committed to the translation of life-saving therapies for acute hepatic diseases, where the medical need is dramatically high.

A life-saving therapy

Versantis’ lead product candidate, VS-01, is the first treatment for acute-on-chronic liver failure (ACLF), a life-threatening condition of high unmet medical need. The mortality of ACLF patients is alarming due to multi-organ failures resulting in dangerous accumulations of toxins in the blood. The versatile mechanism of action of VS-01 can simultaneously support the affected organs (liver, kidneys, brain), encourage liver regeneration, and save patients’ lives.

discover the full potential of our pipeline...


Oct 2016
Versantis made it into the Top13 of MassChallenge!

Sep 2016
Versantis in the Top10 of the best Swiss Biotech Startups.

Jul 2016
Versantis wins a Cydan scholarship!

Jun 2016
Japanese patent granted!

May 2016
EMA Orphan Drug Designation granted to VS-01! 

more news and more details...

Awards and supports



Versantis AG
c/o ETH Zurich
Otto-Stern-Weg 7, HPL D16.2
8093 Zurich


Copyright © 2016
Versantis AG